Literature DB >> 25572005

Beyond traditional pharmacology: new tools and approaches.

E V Gurevich1, V V Gurevich1.   

Abstract

Traditional pharmacology is defined as the science that deals with drugs and their actions. While small molecule drugs have clear advantages, there are many cases where they have proved to be ineffective, prone to unacceptable side effects, or where due to a particular disease aetiology they cannot possibly be effective. A dominant feature of the small molecule drugs is their single mindedness: they provide either continuous inhibition or continuous activation of the target. Because of that, these drugs tend to engage compensatory mechanisms leading to drug tolerance, drug resistance or, in some cases, sensitization and consequent loss of therapeutic efficacy over time and/or unwanted side effects. Here we discuss new and emerging therapeutic tools and approaches that have potential for treating the majority of disorders for which small molecules are either failing or cannot be developed. These new tools include biologics, such as recombinant hormones and antibodies, as well as approaches involving gene transfer (gene therapy and genome editing) and the introduction of specially designed self-replicating cells. It is clear that no single method is going to be a 'silver bullet', but collectively, these novel approaches hold promise for curing practically every disorder.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25572005      PMCID: PMC4500362          DOI: 10.1111/bph.13066

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  129 in total

1.  Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations.

Authors:  Frank Soldner; Josée Laganière; Albert W Cheng; Dirk Hockemeyer; Qing Gao; Raaji Alagappan; Vikram Khurana; Lawrence I Golbe; Richard H Myers; Susan Lindquist; Lei Zhang; Dmitry Guschin; Lauren K Fong; B Joseph Vu; Xiangdong Meng; Fyodor D Urnov; Edward J Rebar; Philip D Gregory; H Steve Zhang; Rudolf Jaenisch
Journal:  Cell       Date:  2011-07-14       Impact factor: 41.582

Review 2.  G-protein-coupled receptors: turn-ons and turn-offs.

Authors:  C V Carman; J L Benovic
Journal:  Curr Opin Neurobiol       Date:  1998-06       Impact factor: 6.627

Review 3.  Assessment of the metabolism of therapeutic proteins and antibodies.

Authors:  Eric Ezan; François Becher; François Fenaille
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-06-04       Impact factor: 4.481

4.  Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin.

Authors:  Sathya R Sriram; Xiaojie Li; Han Seok Ko; Kenny K K Chung; Esther Wong; Kah Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Hum Mol Genet       Date:  2005-07-27       Impact factor: 6.150

5.  How does arrestin respond to the phosphorylated state of rhodopsin?

Authors:  S A Vishnivetskiy; C L Paz; C Schubert; J A Hirsch; P B Sigler; V V Gurevich
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

6.  Engineering visual arrestin-1 with special functional characteristics.

Authors:  Sergey A Vishnivetskiy; Qiuyan Chen; Maria C Palazzo; Evan K Brooks; Christian Altenbach; Tina M Iverson; Wayne L Hubbell; Vsevolod V Gurevich
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

7.  RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.

Authors:  Stephen J Gold; Chau V Hoang; Bryan W Potts; Gregory Porras; Elsa Pioli; Ki Woo Kim; Agnes Nadjar; Chuan Qin; Gerald J LaHoste; Qin Li; Bernard H Bioulac; Jeffrey L Waugh; Eugenia Gurevich; Rachael L Neve; Erwan Bezard
Journal:  J Neurosci       Date:  2007-12-26       Impact factor: 6.167

8.  Enhanced arrestin facilitates recovery and protects rods lacking rhodopsin phosphorylation.

Authors:  Xiufeng Song; Sergey A Vishnivetskiy; Owen P Gross; Katrina Emelianoff; Ana Mendez; Jeannie Chen; Eugenia V Gurevich; Marie E Burns; Vsevolod V Gurevich
Journal:  Curr Biol       Date:  2009-04-09       Impact factor: 10.834

9.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

10.  RNA-guided editing of bacterial genomes using CRISPR-Cas systems.

Authors:  Wenyan Jiang; David Bikard; David Cox; Feng Zhang; Luciano A Marraffini
Journal:  Nat Biotechnol       Date:  2013-01-29       Impact factor: 54.908

View more
  9 in total

1.  British Pharmacological Society, 5th Focused Meeting on Cell Signalling: Matters arising ….

Authors:  Gary B Willars; Andrew B Tobin; R A John Challiss
Journal:  Br J Pharmacol       Date:  2015-07       Impact factor: 8.739

2.  Differential manipulation of arrestin-3 binding to basal and agonist-activated G protein-coupled receptors.

Authors:  Susanne Prokop; Nicole A Perry; Sergey A Vishnivetskiy; Andras D Toth; Asuka Inoue; Graeme Milligan; Tina M Iverson; Laszlo Hunyady; Vsevolod V Gurevich
Journal:  Cell Signal       Date:  2017-04-28       Impact factor: 4.315

Review 3.  Hypusinated EIF5A as a feasible drug target for Advanced Medicinal Therapies in the treatment of pathogenic parasites and therapy-resistant tumors.

Authors:  Annette Kaiser; Enzo Agostinelli
Journal:  Amino Acids       Date:  2022-01-09       Impact factor: 3.520

Review 4.  Integrating plant molecular farming and materials research for next-generation vaccines.

Authors:  Young Hun Chung; Derek Church; Edward C Koellhoffer; Elizabeth Osota; Sourabh Shukla; Edward P Rybicki; Jonathan K Pokorski; Nicole F Steinmetz
Journal:  Nat Rev Mater       Date:  2021-12-06       Impact factor: 76.679

5.  Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors.

Authors:  Daniel Tobias Michaeli; Hasan Basri Yagmur; Timur Achmadeev; Thomas Michaeli
Journal:  Ther Innov Regul Sci       Date:  2022-01-11       Impact factor: 1.778

Review 6.  Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One.

Authors:  Alessandra Salerno; Francesca Seghetti; Jessica Caciolla; Elisa Uliassi; Eleonora Testi; Melissa Guardigni; Marinella Roberti; Andrea Milelli; Maria Laura Bolognesi
Journal:  J Med Chem       Date:  2022-07-11       Impact factor: 8.039

7.  Value drivers of development stage biopharma companies.

Authors:  Daniel Tobias Michaeli; Hasan Basri Yagmur; Timur Achmadeev; Thomas Michaeli
Journal:  Eur J Health Econ       Date:  2022-01-17

8.  How genetic errors in GPCRs affect their function: Possible therapeutic strategies.

Authors:  Henriette Stoy; Vsevolod V Gurevich
Journal:  Genes Dis       Date:  2015-06

9.  βArrestin2 Mediates Renal Cell Carcinoma Tumor Growth.

Authors:  Jude Masannat; Hamsa Thayele Purayil; Yushan Zhang; Michelle Russin; Iqbal Mahmud; Wanju Kim; Daiqing Liao; Yehia Daaka
Journal:  Sci Rep       Date:  2018-03-20       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.